A new therapy for patients with chronic lymphocytic leukaemia is on the November reimbursement list.
The reimbursement of another innovative therapy in PBL is an important step - it shows the consistency and comprehensiveness of the Ministry of Health's approach to the care of patients with PBL: three years ago a breakthrough therapy was reimbursed in the third line of treatment, two years ago patients were given access to the innovation in the second line, and now the innovative therapy will be available to Polish patients already in the first line of treatment.
Source: medexpress.co.uk